Physician profile
Yiling Zeng
NPI 1922348390
$3,541.40
in general payments reported to CMS, 2019-2025
24 companies · $1,521 in 2025
The $1,521 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $429 · 2022: $628 · 2023: $549 · 2024: $414 · 2025: $1,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,483.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $644.87 | 2023-2025 | Vemlidy, Livdelzi |
| Astrazeneca Pharmaceuticals LP | $571.57 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Amarin Pharma, INC. | $391.06 | 2021-2023 | |
| Esperion Therapeutics, INC. | $378.95 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.91 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $222.99 | 2022-2024 | Mounjaro, Jardiance, Trulicity |
| Glaxosmithkline, LLC. | $176.92 | 2021-2025 | Trelegy Ellipta, Nucala |
| Bridgebio Pharma, INC. | $150.00 | 2025 | Attruby |
| Agios Pharmaceuticals, INC. | $137.78 | 2025 | Pyrukynd |
| Novo Nordisk INC | $105.71 | 2022-2023 | Rybelsus, Ozempic |
| Amgen INC. | $65.83 | 2024-2025 | Evenity, Prolia, Prolia |
| Seqirus USA INC | $52.77 | 2022-2025 | Flucelvax, Fluad |
| Exact Sciences Corporation | $50.00 | 2023-2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $47.88 | 2024 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $45.64 | 2024-2025 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $39.87 | 2022 | |
| Axsome Therapeutics, INC. | $34.36 | 2025 | Auvelity |
| Medtronic, INC. | $28.13 | 2025 | Percept PC Brainsense |
| Lundbeck LLC | $26.25 | 2025 | Rexulti |
| Agepha Pharma Fz LLC | $25.00 | 2025 | Lodoco |
| Ardelyx, INC. | $25.00 | 2025 | Ibsrela |
| Ibsa Pharma INC. | $20.49 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $20.42 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.00 | 2024 | Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yiling Zeng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.